Shilpa Gupta, MD
Hematology & Oncology · Minneapolis, MNNPI 1548455355
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.9%. Among hematology & oncology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 366 payments — averaging $1151.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$84K
- E.r. Squibb & Sons, L.L.C.$63K
- EMD Serono, Inc.$40K
- AstraZeneca$37K
- Pfizer$32K
- Johnson & Johnson$30K
- plus $135K from 22 others
Across 836 payments — averaging $18,993 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$6.4M
- Novartis$3.4M
- Merck$2.7M
- Pfizer$805K
- Genentech, Inc.$633K
- Exelixis Inc.$532K
- plus $1.3M from 13 others
What the payments were for
- Consulting fees$178,82642%
- Speaking & faculty fees$174,09941%
- Travel & lodging$56,15813%
- Food & beverage$8,3712%
- Education$4,0001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 62 | $83,937 |
| E.r. Squibb & Sons, L.L.C. | 57 | $63,268 |
| EMD Serono, Inc. | 33 | $39,771 |
| AstraZeneca | 28 | $37,290 |
| Pfizer | 30 | $31,992 |
| Johnson & Johnson | 24 | $30,234 |
| Gilead | 28 | $29,919 |
| Astellas Pharma Europe Ltd | 17 | $27,812 |
| Seagen Inc. | 32 | $26,232 |
| Exelixis Inc. | 10 | $13,283 |
| Janssen Scientific Affairs, LLC | 4 | $5,420 |
| Janssen Research & Development, LLC | 4 | $4,736 |
| Foundation Medicine, Inc. | 1 | $3,893 |
| Novartis | 3 | $3,588 |
| Bayer | 1 | $3,425 |
| AVEO Pharmaceuticals, Inc. | 5 | $3,237 |
| Astellas Pharma US Inc | 5 | $2,851 |
| Sanofi | 5 | $2,678 |
| Janssen Global Services, LLC | 3 | $2,328 |
| Astellas Pharma Global Development | 1 | $1,875 |
| F. Hoffmann-la Roche AG | 3 | $1,682 |
| Eli Lilly | 3 | $1,505 |
| Genentech USA, Inc. | 2 | $162 |
| Genentech, Inc. | 1 | $149 |
| EMD Serono Research & Development Institute, Inc. | 1 | $112 |
| Urogen Pharma, Inc. | 1 | $36 |
| Telix Pharmaceuticals | 1 | $24 |
| Genmab U.S., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$421,455 in reported general payments places this provider in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 61 | $872,679 |
| CabometyxCabozantinib S-Malate | 23 | $384,751 |
| XtandiEnzalutamide | 31 | $257,144 |
| LenvimaLenvatinib Mesylate | 18 | $238,972 |
| LynparzaOlaparib | 15 | $198,410 |
| OrgovyxRelugolix | 50 | $128,754 |
| Abiraterone Acetate | 53 | $97,045 |
| Everolimus | 11 | $48,349 |
| Ondansetron Hcl | 11 | $1,122 |
| Dexamethasone | 26 | $791 |
| Prednisone | 69 | $353 |
| Prochlorperazine Maleate | 14 | $235 |
| Bicalutamide | 12 | $199 |
| Ondansetron OdtOndansetron | 11 | $154 |
| Levothyroxine Sodium | 15 | $136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $30,234 | $872,67961 claims |
| Exelixis Inc.Cabometyx | $13,283 | $384,75123 claims |
| Astellas Pharma US IncXtandi | $2,851 | $257,14431 claims |
| AstraZenecaLynparza | $37,290 | $198,41015 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $5,420 | $97,04553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Other hematology & oncology in Minneapolis
- Mark RedingMinneapolis$519K
- Vicki MorrisonMinneapolis$354K
- Aimee MerinoMinneapolis$161K
- Daniel WeisdorfMinneapolis$64K
- Gautam JhaMinneapolis$55K
- Arpit RaoMinneapolis$46K
- Amit KulkarniMinneapolis$40K
- Gregory VercellottiMinneapolis$34K
- Veronika BachanovaMinneapolis$33K
- Marshall MazepaMinneapolis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.